Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Level Four Advisory Services LLC

Level Four Advisory Services LLC lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 33,870 shares of the biopharmaceutical company’s stock after selling 185 shares during the quarter. Level Four Advisory Services LLC’s holdings in Gilead Sciences were worth $3,129,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in GILD. Slagle Financial LLC raised its stake in shares of Gilead Sciences by 4.1% during the 4th quarter. Slagle Financial LLC now owns 28,124 shares of the biopharmaceutical company’s stock valued at $2,598,000 after buying an additional 1,100 shares during the last quarter. denkapparat Operations GmbH purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $1,142,000. Premier Fund Managers Ltd lifted its holdings in Gilead Sciences by 46.7% in the fourth quarter. Premier Fund Managers Ltd now owns 15,710 shares of the biopharmaceutical company’s stock valued at $1,445,000 after acquiring an additional 5,000 shares during the period. Orion Portfolio Solutions LLC boosted its position in Gilead Sciences by 3.7% in the 4th quarter. Orion Portfolio Solutions LLC now owns 90,026 shares of the biopharmaceutical company’s stock worth $8,316,000 after purchasing an additional 3,224 shares in the last quarter. Finally, New Age Alpha Advisors LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $10,778,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.6 %

Shares of NASDAQ:GILD opened at $111.79 on Friday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The stock has a market cap of $139.22 billion, a P/E ratio of 302.14, a PEG ratio of 0.71 and a beta of 0.21. The business has a fifty day moving average of $105.48 and a two-hundred day moving average of $94.81. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.83%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Cantor Fitzgerald reissued a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. The Goldman Sachs Group raised their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Morgan Stanley upped their price target on Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a report on Tuesday, March 11th. BMO Capital Markets raised their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Finally, Oppenheimer upped their target price on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 4th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $105.12.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. This trade represents a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 302,785 shares of company stock valued at $30,503,250 over the last quarter. 0.16% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.